Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10–13 ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...

The European Medicines Association (EMA) has upheld its decision to recommend the Alzheimer’s drug lecanemab despite concerns that any clinical benefits are small and there is a risk of brain swelling ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...